{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-22-004080","form_type":"8-K","ticker":"AUPH","cik":"0001600620","company_name":"Aurinia Pharmaceuticals Inc.","filed_at":"2022-02-28T23:59:59+00:00","discovered_at":"2026-05-14T18:04:07.303393+00:00","generated_at":"2026-06-27T03:39:00.670991+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Aurinia Q4 net revenue $23.4M, FY loss $181M; FY22 LUPKYNIS guidance $115-135M","bullets":["Q4 2021 net revenue $23.4M (60% increase from Q3); full year net revenue $45.6M.","Net loss Q4 $33.3M ($0.25/share) vs $8.1M ($0.06) in Q4 2020; full year $181M ($1.40/share).","FY 2022 LUPKYNIS net revenue guidance $115-135M, representing 150-200% YoY growth.","Cash, equivalents & investments $466.1M at Dec 31, 2021; raised $196.7M net via ATM at avg $19.91.","AURORA 2 continuation study shows sustained efficacy; EMA MAA on track for CHMP opinion H2 2022."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-22-004080","json":"https://secwatch.observer/filing/0001628280-22-004080.json","markdown":"https://secwatch.observer/filing/0001628280-22-004080.md","text":"https://secwatch.observer/filing/0001628280-22-004080.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1600620/000162828022004080/0001628280-22-004080-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1600620/000162828022004080/auph-20220228.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-27T03:39:00.670991+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}